VTGN VistaGen Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VTGN

Price (delayed)

$0.5714

Market cap

$22.64M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.9

Enterprise value

-$23.3M

?
Relative Growth: Rel. Growth: 29
Relative Strength: Rel. Strength: 3
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 21

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and ...

Highlights
The company's debt fell by 23% QoQ and by 17% YoY
The gross profit has grown by 13% YoY and by 10% from the previous quarter
VTGN's quick ratio has dropped by 50% year-on-year and by 19% since the previous quarter
The net income has declined by 42% year-on-year and by 8% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.vistagen.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of VTGN

VTGN stock price

How has the VistaGen Therapeutics stock price performed over time
Intraday
2.02%
1 week
-9.77%
1 month
-8.21%
1 year
-76.09%
YTD
-13.67%
QTD
-0.02%

Financial performance

How have VistaGen Therapeutics's revenue and profit performed over time
Revenue
$790,000
Gross profit
$790,000
Operating income
-$69.9M
Net income
-$67.05M
Gross margin
100%
Net margin
-8,486.8%
The net income has declined by 42% year-on-year and by 8% since the previous quarter
The company's operating income fell by 32% YoY and by 7% QoQ
The company's net margin fell by 25% YoY
The operating margin is down by 17% year-on-year but it is up by 2.6% since the previous quarter

Price vs fundamentals

How does VTGN's price correlate with its fundamentals

Growth

What is VistaGen Therapeutics's growth rate over time

Valuation

What is VistaGen Therapeutics stock price valuation
P/E
N/A
P/B
0.44
P/S
30.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-29.5
VistaGen Therapeutics's EPS has decreased by 28% YoY
The price to book (P/B) is 81% lower than the 5-year quarterly average of 2.3 and 61% lower than the last 4 quarters average of 1.1
The equity has decreased by 37% YoY and by 23% QoQ
The price to sales (P/S) is 74% lower than the last 4 quarters average of 117.2
VistaGen Therapeutics's revenue has increased by 13% YoY and by 10% QoQ

Efficiency

How efficient is VistaGen Therapeutics business performance
The ROE has plunged by 128% YoY and by 21% from the previous quarter
The company's return on assets has shrunk by 105% YoY and by 18% QoQ
The company's return on invested capital fell by 46% YoY and by 23% QoQ
VistaGen Therapeutics's ROS has decreased by 25% YoY

Dividends

What is VTGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VTGN.

Financial health

How did VistaGen Therapeutics financials performed over time
The current ratio has plunged by 50% YoY and by 19% from the previous quarter
VTGN's quick ratio has dropped by 50% year-on-year and by 19% since the previous quarter
The company's debt is 97% lower than its equity
VTGN's debt to equity has surged by 50% year-on-year
The equity has decreased by 37% YoY and by 23% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.